Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 15;195(10):1300-1310.
doi: 10.1164/rccm.201606-1227CI.

New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations

Elizabeth P Harausz  1 , Anthony J Garcia-Prats  2 , James A Seddon  3 , H Simon Schaaf  2 , Anneke C Hesseling  2 , Jay Achar  4 , Jonathan Bernheimer  5 , Andrea T Cruz  6 , Lia D'Ambrosio  7   8 , Anne Detjen  9 , Stephen M Graham  10 , Jennifer Hughes  5 , Sylvie Jonckheere  11 , Ben J Marais  12 , Giovanni Battista Migliori  7 , Lindsay McKenna  13 , Alena Skrahina  14 , Marina Tadolini  15 , Peyton Wilson  16 , Jennifer Furin  17 ; Sentinel Project on Pediatric Drug-Resistant Tuberculosis
Affiliations
Free article
Review

New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations

Elizabeth P Harausz et al. Am J Respir Crit Care Med. .
Free article

Abstract

It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.

Keywords: Mycobacterium tuberculosis; adolescent; child; multidrug-resistant tuberculosis; pediatric.

PubMed Disclaimer

Substances